

CURRICULUM VITAE

Name and Surname:	Tuğba Gül İnci
Academic Title:	Assistant Professor
Work Address:	
Email:	tinci@biruni.edu.tr
Area of Expertise:	Engineering and Technology Health Sciences Natural Sciences

PUBLICATIONS

A. Articles published in international peer-reviewed journals:

- A1.** İnci T. G., Ugurel E., Orleoco M., Akar S., Atlı R., Danis O., Turgut-balık D., "Cloning, Expression, Purification and Biological Activity Analysis of Recombinant *Helicobacter pylori* FabI as a Drug Target", *Molecular Biotechnology*, vol. 68, no. 2, pp. 846-853, 2026.
- A2.** İnci T. G., Acar S., Turgut-balık D., "Nonsmall-cell lung cancer treatment: current status of drug repurposing and nanoparticle-based drug delivery systems", *Turkish Journal of Biology*, vol. 48, no. 2, 2024.
- A3.** Dinparvar S., Abamor E. Ş., Öztav S., İnci T. G., İhlamur M., Baghirova M., Balık D., Allahverdiyev A., "Evaluation of in vitro immunostimulatory and cytotoxic effects of recombinant survivin protein in combination with doxorubicin and breast cancer antigen-loaded polycaprolactone nanoparticles", *Nano Futures*, vol. 7, no. 3, 2023.
- A4.** Mutlu O., Ugurel O. M., Sariyer E., Ata O., İnci T. G., Ugurel E., Kocer S., Turgut-balık D., "Targeting SARS-CoV-2 Nsp12/Nsp8 interaction interface with approved and investigational drugs: an in silico structure-based approach", *Journal of Biomolecular Structure and Dynamics*, vol. 40, no. 2, pp. 918-930, 2022.
- A5.** Ugurel O. M., Mutlu O., Sariyer E., Kocer S., Ugurel E., İnci T. G., Ata O., Turgut-balık D., "Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13)", *International Journal of Biological Macromolecules*, vol. 163, pp. 1687-1696, 2020.

D. Articles published in national peer-reviewed journals:

- D1.** Ugurel E., Kocer S., Sariyer E., Mutlu O., İnci T. G., Ugurel O. M., Turgut-balık D., "Heterologous expression, biochemical characterisation and computational analysis of *Bacteroides fragilis* enolase", *Computational Biology and Chemistry*, 2022.